期刊文献+

利福平PLGA纳米粒的制备及雾化吸入给药后在大鼠体内的药动学 被引量:2

Preparation and Pharmacokinetics of Rifampicin-loaded PLGA Nanoparticles after Nebulized Inhalation in Rats
下载PDF
导出
摘要 [目的]制备利福平PLGA纳米粒,考察其体外释放特性并评价该纳米粒在大鼠体内的药动学特征。[方法]以乳酸-羟基乙酸共聚物(PLGA)为载体,采用改良的自乳化溶剂蒸发法制备利福平PLGA纳米粒,考察其形态、粒径、包封率、载药量,采用透析袋法研究其体外释放特性,考察纳米粒经雾化吸入给药后在大鼠体内的药动学特征。[结果]制备的纳米粒外观呈球形或类球形,平均粒径为(128.73±4.07)nm,包封率和载药量分别为(65.84±1.08)%和(3.78±0.14)%。药动学结果显示,纳米粒组的tmax是溶液组6倍,Cmax比溶液组降低30%。[结论]采用改良的自乳化溶剂蒸发法可成功制备利福平PLGA纳米粒;经雾化吸入给药后,能显著减缓利福平进入体循环的速度并使药物全身暴露减少,具备进一步开发价值。 [Objective]To prepare Rifampicin-loaded PLGA nanoparticles and evaluate the in vitro release behavior and the pharmacokinetics of the nano-particles in rats.[Method] The rifampicin nanoparticles with PLGA as carrier material were prepared by a modified spontaneous emulsification solvent diffusion method and characterized in terms of shape,particle size,encapsulation efficiency and drug loading.The in vitro release behavior was determined by dialysis method and the pharmacokinetics of the nanoparticles after nebulized inhalation in rats was evaluated.[Result] The optimal nanoparticles were spherical with the mean diameter of(128.73±4.07)nm.The encapsulation efficiency was(65.84±1.08)% and drug loading was(3.78±0.14)%.The pharmacokinetics results showed that tmax of nanoparticles group was increased by 6 times while the Cmax was nearly 30% lower than the solution group.[Conclusion] Rifampicin-loaded PLGA nanoparticles were successfully prepared by a modified spontaneous emulsification solvent diffusion method.The nanoparticles with slower absorption after nebulized inhalation as well as the less general exposure dose would be worthy of further study.
出处 《浙江中医药大学学报》 CAS 2013年第5期502-505,共4页 Journal of Zhejiang Chinese Medical University
基金 国家自然科学基金资助项目(30772793) 杭州市医药卫生科技计划项目(2010Z007)~~
关键词 利福平 纳米粒 制备 雾化吸入 药动学 rifampicin nanoparticle preparation nebulized inhalation pharmacokinetics
  • 相关文献

参考文献13

  • 1Perry S, Hussain R, Parsonnet J. The impact of mucosal infections on acquisition and progression of uberculosis [J]. Mucosal Immunol, 2011, 4(3): 246-251. 被引量:1
  • 2Ohashi K, Kabasawa T, Ozeki T, et al. One-step preparation of rifampicin/poly(lacticoglycolic acid)nanop- article-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis[J]. J Control Release, 2009, 135(1):19-24. 被引量:1
  • 3Forget E J, Menzies D. Adverse reactions to first-line antitubereulosis drugs[J]. Expert Opin Drug Saf, 2006, 5(2): 231-249. 被引量:1
  • 4Bawarski WE, Chidlowsky E, Bharali D J, et al. Emerging nanopharmaceuticals[J]. Nanomedicine,2008,4(4):273-282. 被引量:1
  • 5Sharma A, Pandey R, Sharma S, et al. Chemotherapeutic efficacy of poly(DL-lactide-co-glycolide) nanoparticle en- capsulated antitubercular drugs at sub-therapeutic dose against experimental tubereulosis[J]. Int J Antimicrob Agents, 2004, 24(6): 599-604. 被引量:1
  • 6Panyam J, Dali MM, Sahoo SK, et al. Polymer degradation and in vitro release of a model protein from poly(D,L- lactide-co-glycolide) nano-and microparticles[J]. J Control Release, 2003, 92(1-2):173-187. 被引量:1
  • 7刘明星,董静,杨亚江,杨祥良,徐辉碧.雷公藤甲素聚乳酸纳米粒的制备及毒性[J].药学学报,2004,39(7):556-560. 被引量:29
  • 8李范珠.大鼠股动静脉插管体外部分的保护装置:中国,2912560[P].2007-06-20. 被引量:2
  • 9Ahmad Z, Shaiana S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis[J]. Int J Antimicrob Agents, 2005, 26(4): 298-303. 被引量:1
  • 10Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegradable polymeric nanoparticles as drug delivery devices[J]. J Control Release, 2001, 70(1-2): 1-20. 被引量:1

二级参考文献3

共引文献29

同被引文献34

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部